This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Examining the potential for Mirati's FDA approved KRAS drug, Krazati (adagrasib) in treating non-small cell lung cancer
Ticker(s): MRTXWho's the expert?
Institution: University of Colorado
- Chair in Cancer Research, Distinguished Professor, Medicine-Medical Oncology, & Founding Director of the University of Colorado Cancer Center.
- Past president of the International Association for the Study of Lung Cancer (IASLC) and the American Society of Clinical Oncology (ASCO); served as chairman of the FDA Oncology Drug Advisory Committee.
- Currently managing 4 patients with mesothelioma.
- Research focuses on novel molecular therapies and immunotherapies for lung cancer and other thoracic cancers.
Interview GoalThis interview will focus on the potential use of Krazati (adagrasib) in treating non-small cell lung cancer.
The FDA recently granted accelerated approved for adagrasib (Krazati, Mirati Therapeutics, Inc.) for people with metastatic or locally advanced non-small cell lung cancer (NSCLC), whose tumors contained a KRAS G12C mutation, and whose tumor was growing despite having had prior therapy We will dig into the findings from the phase 2 KRYSTAL-1 trial.
The FDA recently granted accelerated approved for adagrasib (Krazati, Mirati Therapeutics, Inc.) for people with metastatic or locally advanced non-small cell lung cancer (NSCLC), whose tumors contained a KRAS G12C mutation, and whose tumor was growing despite having had prior therapy We will dig into the findings from the phase 2 KRYSTAL-1 trial.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
